Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Mavefund
Dashboard
Neurosense Therapeutics Ltd logo
NRSN

Neurosense Therapeutics Ltd

MaveScore 10 Low model confidence
Last Price US$0.70 As of Jun 29, 2026
Market Cap US$26.2m Company size context
7D Performance -9.60% Past 7 days
1Y Performance -67.04% Past 12 months
Model Rating
Historical model output for research review

Fundamental data date

Updating

Refreshing

Market price date

Jun 29, 2026

1 day old

Coverage

10/16

6 missing model inputs

Data quality

Review

Partial or delayed snapshot

Transparent research score

Why the model scores this stock

MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

MaveScore 10 Low confidence

Stored data quality

Freshness and coverage checks

Stored company inputs are available, but some dates or model fields are older or incomplete.

10/16 Partial or delayed snapshot

Quality

Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

7/35 Weak

Financial Strength

Financial strength needs live profitability and cash-flow fields.

0/25 Needs Data

Valuation Support

Valuation needs price plus per-share earnings, cash-flow, or book-value inputs.

0/15 Needs Data

Momentum

Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

3/15 Weak

Shareholder Alignment

Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

0/10 Weak

Positive model output

More live company inputs are needed before positive research signals can be surfaced.

Research risks to review

  • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
  • Financial strength needs live profitability and cash-flow fields.
  • Valuation needs price plus per-share earnings, cash-flow, or book-value inputs.

MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include return on equity, net margin, gross margin, free cash flow per share, book value per share, earnings per share.

Overview Price History News SEC Filings Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
Dashboard Funda..tals Deep..lue Prediction Screener Map

Neurosense Therapeutics Ltd Overview

Industry: Biotechnology

Sector: Healthcare

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Neurosense Therapeutics Ltd is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

Score

Price History & Performance

Review Neurosense Therapeutics Ltd in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

Recent News



News Image
Will NRSN stock pay special dividends - 2025 Institutional Moves & Daily Stock Momentum Reports
1 hour ago
News Image
Will NRSN stock maintain momentum in 2025 - 2025 Top Decliners & Technical Confirmation Trade Alerts
Yesterday
News Image
Can NRSN stock hit record highs again - Portfolio Gains Report & Daily Risk Controlled Trade Plans
Yesterday

Neurosense Therapeutics Ltd Competitors

Neurosense Therapeutics Ltd operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

Earnings Per Share

EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

Continue the analysis

Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

View plans
Ticker Image

Neurosense Therapeutics Ltd

US$0.70

US$26.2m

-9.60%

-67.04%